Investigating a genetic variant's role in lung injury during sepsis
Haptoglobin 2 variant and endothelial glycocalyx shedding in sepsis-induced ARDS
This study is looking at how a specific gene might influence lung problems in people with sepsis, aiming to find early signs of lung injury so we can develop better treatments for those experiencing acute respiratory distress syndrome (ARDS).
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-10907623 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific genetic variant, known as haptoglobin 2, affects the degradation of a protective layer in the lungs during sepsis-induced acute respiratory distress syndrome (ARDS). The study aims to identify early triggers that lead to this degradation, which is crucial for developing new treatments. By examining the relationship between cell-free hemoglobin and lung injury, the research seeks to uncover potential therapeutic targets that could prevent or mitigate ARDS in patients with sepsis. Patients participating in this research may undergo assessments related to their genetic makeup and lung function.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with sepsis who have the haptoglobin 2 genetic variant and are at risk for developing ARDS.
Not a fit: Patients without sepsis or those who do not carry the haptoglobin 2 variant may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for preventing or treating ARDS in patients with sepsis.
How similar studies have performed: Previous research has indicated that understanding genetic factors in sepsis can lead to significant advancements in treatment, suggesting this approach has potential for success.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Ware, Lorraine B — Vanderbilt University Medical Center
- Study coordinator: Ware, Lorraine B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.